Part 1: The need for novel treatment regimens for ANCA-associated vasculitis.
Merkel
P A
PA
Boston University School of Medicine, Boston, MA 02118, USA. pmerkel@bu.edu
D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D001685:Biological Factors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D055502:Secondary Prevention; D017211:Treatment Failure; D014657:Vasculitis / Q000276:immunology / Q000628:therapy*
D019268:Antibodies, Antineutrophil Cytoplasmic; D001685:Biological Factors; D007166:Immunosuppressive Agents